Biogened SA

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLBIOGN00018
PLN
21.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Debt Company with a Debt to Equity ratio (avg) at times

  • High Debt Company with a Debt to Equity ratio (avg) at times
  • The company has been able to generate a Return on Equity (avg) of 8.84% signifying low profitability per unit of shareholders funds
2

Negative results in Mar 25

3

With ROE of 10.45%, it has a fair valuation with a 1.33 Price to Book Value

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 51 Million (Micro Cap)

stock-summary
P/E

13.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

120.19%

stock-summary
Debt Equity

0.44

stock-summary
Return on Equity

10.23%

stock-summary
Price to Book

1.17

Revenue and Profits:
Net Sales:
33 Million
(Quarterly Results - Mar 2025)
Net Profit:
2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.78%
0%
-2.78%
6 Months
-14.63%
0%
-14.63%
1 Year
-22.22%
0%
-22.22%
2 Years
-22.22%
0%
-22.22%
3 Years
72.13%
0%
72.13%
4 Years
77.97%
0%
77.97%
5 Years
55.56%
0%
55.56%

Biogened SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
18.77%
EBIT Growth (5y)
17.39%
EBIT to Interest (avg)
4.85
Debt to EBITDA (avg)
1.29
Net Debt to Equity (avg)
0.40
Sales to Capital Employed (avg)
1.72
Tax Ratio
33.00%
Dividend Payout Ratio
42.19%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.92%
ROE (avg)
8.84%

Valuation key factors

Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
1.33
EV to EBIT
9.58
EV to EBITDA
6.30
EV to Capital Employed
1.23
EV to Sales
0.69
PEG Ratio
5.19
Dividend Yield
105.04%
ROCE (Latest)
12.85%
ROE (Latest)
10.45%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 11.15% vs 16.08% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 9.52% vs 10.53% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "32.90",
          "val2": "29.60",
          "chgp": "11.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.60",
          "val2": "4.80",
          "chgp": "16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.80",
          "chgp": "25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.30",
          "val2": "2.10",
          "chgp": "9.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "136.40%",
          "val2": "129.10%",
          "chgp": "0.73%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.00% vs 20.10% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 13.73% vs 50.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "110.90",
          "val2": "95.60",
          "chgp": "16.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "13.90",
          "val2": "11.80",
          "chgp": "17.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.50",
          "val2": "2.20",
          "chgp": "13.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5.80",
          "val2": "5.10",
          "chgp": "13.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "88.10%",
          "val2": "92.70%",
          "chgp": "-0.46%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary

Mar'25
Mar'24
Change(%)
Net Sales
32.90
29.60
11.15%
Operating Profit (PBDIT) excl Other Income
5.60
4.80
16.67%
Interest
1.00
0.80
25.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
2.30
2.10
9.52%
Operating Profit Margin (Excl OI)
136.40%
129.10%
0.73%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Mar 2025 is 11.15% vs 16.08% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is 9.52% vs 10.53% in Mar 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
110.90
95.60
16.00%
Operating Profit (PBDIT) excl Other Income
13.90
11.80
17.80%
Interest
2.50
2.20
13.64%
Exceptional Items
0.00
0.00
Consolidate Net Profit
5.80
5.10
13.73%
Operating Profit Margin (Excl OI)
88.10%
92.70%
-0.46%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 16.00% vs 20.10% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 13.73% vs 50.00% in Dec 2023

stock-summaryCompany CV
About Biogened SA stock-summary
stock-summary
Biogened SA
Pharmaceuticals & Biotechnology
Biogened SA is a Poland-based company active in the healthcare sector. The Company is engaged in production and distribution of generic pharmaceuticals in psychiatry, neurology and oncology, as well as development, production and distribution of dermocosmetics and diet supplements. The Company’s product portfolio includes: Polmantis and SST Salvia Stimulating Tablets (pharmaceuticals), Dermedic, Ellexir, Herba Botanic and Novoscabin (dermocosmetics), and Fibers, Prolady, Futimal and Dermedic Caps (diet supplemenst). As of March 31, 2012, Life Science Technologies NV held an 80.92% stake in the capital.
Company Coordinates stock-summary
Company Details
Ul. Pojezierska 99 , LODZ None : 91-342
stock-summary
Tel: 48 42 6513152
stock-summary
Registrar Details